Prenetics Global (NASDAQ:PRE) Cut to “Hold” at Wall Street Zen

Wall Street Zen cut shares of Prenetics Global (NASDAQ:PRE) from a buy rating to a hold rating in a research note published on Saturday.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Prenetics Global in a report on Thursday, January 22nd. Cantor Fitzgerald increased their target price on Prenetics Global from $26.00 to $32.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Prenetics Global currently has a consensus rating of “Hold” and an average price target of $32.00.

Prenetics Global Price Performance

Prenetics Global stock opened at $19.41 on Friday. The stock has a market capitalization of $326.67 million, a P/E ratio of -9.56 and a beta of 0.35. Prenetics Global has a 12-month low of $3.09 and a 12-month high of $20.89. The firm’s 50-day moving average is $16.21 and its two-hundred day moving average is $12.87.

Prenetics Global (NASDAQ:PRE) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.14. Prenetics Global had a negative net margin of 60.70% and a negative return on equity of 30.12%. The business had revenue of $23.56 million for the quarter, compared to the consensus estimate of $26.00 million. As a group, analysts forecast that Prenetics Global will post -3.3 EPS for the current year.

Institutional Trading of Prenetics Global

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Stevens Capital Partners lifted its position in Prenetics Global by 4.7% during the fourth quarter. Stevens Capital Partners now owns 18,207 shares of the company’s stock valued at $287,000 after buying an additional 825 shares in the last quarter. JPMorgan Chase & Co. purchased a new position in shares of Prenetics Global in the 3rd quarter valued at $65,000. UBS Group AG lifted its holdings in shares of Prenetics Global by 581.9% during the 3rd quarter. UBS Group AG now owns 46,561 shares of the company’s stock valued at $619,000 after acquiring an additional 39,733 shares in the last quarter. Finally, Aberdeen Group plc purchased a new stake in Prenetics Global during the 3rd quarter worth $979,000. Institutional investors and hedge funds own 25.01% of the company’s stock.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.